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Background: In Europe, gastric cancer remains diagnosed at advanced stage (serosal and/or lymph node involvement).
Despite curative management combining perioperative systemic chemotherapy and gastrectomy with D1-D2 lymph
node dissection, 5-year survival rates of T3 and/or N + patients remain under 30%. More than 50% of recurrences are
peritoneal and/or locoregional. The use of adjuvant hyperthermic intraperitoneal chemotherapy that eliminates free
cancer cells that can be released into peritoneal cavity during the gastrectomy and prevents peritoneal carcinomatosis
recurrences, was extensively evaluated by several randomized trials conducted in Asia. Two meta-analysis reported that
adjuvant hyperthermic intraperitoneal chemotherapy significantly reduces the peritoneal recurrences and significantly
improves the overall survival. As it was previously done for the evaluation of the extension of lymph node dissection, it
seems very important to validate on European or caucasian patients the results observed in trials performed in Asia.
Methods/design: GASTRICHIP is a prospective, open, randomized multicenter phase III clinical study with two arms
that aims to evaluate the effects of hyperthermic intraperitoneal chemotherapy with oxaliplatin on patients with gastric
cancer involving the serosa and/or lymph node involvement and/or with positive cytology at peritoneal washing,
treated with perioperative systemic chemotherapy and D1-D2 curative gastrectomy. Peroperatively, at the end of
curative surgery, patients will be randomized after preoperatively written consent has been given for participation. Primary
endpoint will be overall survival from the date of surgery to the date of death or to the end of follow-up (5 years).
Secondary endpoint will be 3- and 5-year recurrence-free survival, site of recurrence, morbidity, and quality of life. An
ancillary study will compare the incidence of positive peritoneal cytology pre- and post-gastrectomy in two arms of the
study, and assess its impact on 5-year survival. The number of patients to be randomized was calculated to be 306.
Trial registration: EudraCT number: 2012-005748-12, ClinicalTrials.gov identifier: NCT01882933.
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Stomach is the fourth most common digestive cancer [1],
the second main cause of death from cancer in the world
[2], and the fifth most common cancer in Europe [3].
Surgery
Surgery remains the curative treatment of choice for
stomach cancer. It consists of a radical subtotal or total
gastrectomy with D1 or D2 lymph node Dissection. A
logical and reasonable alternative (expert consensus)
is therefore to carry out D1 dissection associated with
pedicle dissection (common hepatic artery, left gastric
artery and proximal splenic artery). This extension
corresponds to D2 dissection for antral cancers. When
this type of dissection without splenectomy or pan-
creactectomy is carried out for a cancer of the body or
the upper-third of the stomach it is commonly termed
D1.5 dissection. Extending the lymph node dissection
remains controversial. Two randomized studies and a
meta-analysis have shown no benefit from D2 dissection,
although a notable benefit was observed in a sub-group of
patients with lymph node metastasis [4-6]. More recently,
two well-designed, single-arm studies [7,8] showed that
a modified form of D2 dissection or D1.5 dissection,
without splenectomy or pancreatectomy (which increases
post-operative morbidity and mortality) has better results
in terms of survival than D1 dissection, with acceptable
levels of morbidity and mortality.
Neoadjuvant, adjuvant and perioperative treatments
Systemic perioperative chemotherapy is recommended
for the curative treatment of stomach cancer in Europe
since the publication of the MAGIC [9] and Fédération
Française des Centres de Lutte Contre le Cancer (FN
CLCC) - Fédération Française de Chirurgie Digestive
(FFCD) [10] trials. These studies included 503 and 224
patients respectively, presenting with a gastric adenocar-
cinoma or adenocarcinoma of the cardia treated with
surgery associated, or not, with two or three preoperative,
and three postoperative cycles of systemic chemotherapy
(ECF or 5-Fluorouracil (5-FU) cisplatin). The 5-year
survival rate was 36% and 38% respectively in the ex-
perimental arm, compared to 23% and 24% respectively
in the control arm (surgery alone). The postoperative
chemotherapy was not always feasible: only 40% of patients
followed the postoperative treatment regimen in the
MAGIC trial and 50% in the FNCLCC-FFCD trial.
Adjuvant chemo-radiotherapy was shown to be effective
in a phase III study by MacDonald et al. [11] This tested
chemotherapy (FUFA: 5-FU/Folinic Acid) prior to, and
following chemo-radiotherapy (FUFA + 45 Gy) and dem-
onstrated its efficacy in terms of median survival (36 vs
27 months). Two-thirds of the patients include were at
stages T3 or T4 and 85% had node positive. The maincriticism of this trial is that in 54% of cases lymph node
dissection was D0. For many experts, this therefore limits
the applicability of adjuvant chemo-radiotherapy following
resection. This chemo-radiotherapy can be considered as
an alternative for certain patients in good general and
nutritional health with lymph node invasion having under-
gone adequate lymph node Dissection. A retrospective
study suggested that replacing FUFA with simplified
LV5FU2 (Leucovorin/5-FU) reduces toxicity [12]. Another
non-randomized comparative study assessed postoperative
chemo-radiotherapy for patients having undergone D2
dissection of over 85%, and reported a benefit from this
adjuvant treatment for stages IIIA, IIIB and IV [13].
A recent meta-analysis of 17 randomized trials including
a total of 3,838 patients reported a benefit in terms of
overall survival from using systemic postoperative chemo-
therapy 5-FU vs surgery alone [HR 0.83 (95% CI 0.74-
0.94)] [14].
Peritoneal recurrence
Stomach cancer has the highest rate of peritoneal recur-
rence of all digestive cancers. After curative surgery, the
main reason for treatment failure is peritoneal recurrence
which, according to the literature, occurs in 40 to 60% of
cases, despite extensive surgery including D2 lymph node
dissection [15,16].
Several factors favorable to peritoneal recurrence have
been identified: invasion of the serosa (T3, T4 tumors)
[17,18], detection of free cancer cells in the peritoneal
wash liquid [19,20], invasion of the lymph nodes [21],
and signet ring cells adenocarcinoma [22].
Rationale for hyperthermic intraperitoneal chemotherapy
(HIPEC)
The failure rate for curative surgical treatment for patients
with stomach cancer is mainly due to peritoneal recurrence.
It would therefore seem appropriate to offer preventive
treatment to reduce the risk of peritoneal recurrence in
at-risk patients and thereby reduce the failure rate. The
HIPEC technique is increasingly used in the curative
treatment of primary and digestive peritoneal carcin-
omatosis, in association with cytoreductive surgery [23-25].
It is recommended for treating pseudomyxoma peritonei
and peritoneal mesothelioma [25,26] and it is currently
being assessed in France for use in the curative and
preventive treatment of colorectal and ovarian carcinoma-
tosis in several phase III studies funded by the French
clinical research projects funding program (PHRC):
PRODIGE 7/ACCORD 15/0608 (ClinicalTrials.gov number
NCT00769405, ProphyloCHIP (ClinicalTrials.gov number:
NCT01226394), CHIPOR (ClinicalTrials.gov number
NCT01376752).
Intraperitoneal chemotherapy has the advantage of
putting the intraperitoneal tumor tissue (which at the
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cancer cells into direct contact with high concentrations
of cytotoxic agents, limiting the systemic concentrations
and thereby the risk of toxicity. The cytotoxic effect of
heating to 42.5°C has been demonstrated in vitro [27]
and it has also been demonstrated that the hyperthermia
increases the effectiveness of certain molecules (mito-
mycin C, cisplatin, oxaliplatin), either by increasing their
cytotoxicity, or by increasing their penetration into the
tumor tissue [28,29].
Results for HIPEC used as a curative and preventive
treatment for gastric cancer
For gastric carcinomatosis, the association of complete
cytoreductive surgery (CCS) and HIPEC is the only thera-
peutic strategy to achieve long-term survival. A retrospect-
ive study of 159 patients with gastric carcinomatosis
treated with CCS and HIPEC, reported a 5-year survival
rate of 23%. These extended survival rates was obtained
in rigorously selected patients presenting with local,
resectable carcinomatosis [30]. A recent randomized phase
III study demonstrated the benefit of HIPEC (cisplatin and
mitomycin C) associated with CCS. Median survival was
11 months in the CCS +HIPEC group as compared to
6.5 months in the group receiving CCS alone (p = 0.046)
[31]. The benefit of HIPEC was greater in patients with
synchronous carcinomatosis.
Several asian authors have reported a potential benefit
from using intraperitoneal chemotherapy with or without
hyperthermia, as a complement to curative surgery, in the
absence of carcinomatosis [32-34].
Fujimoto et al. [35] recruited 141 patients and showed
that HIPEC significantly reduced the incidence of periton-
eal recurrence (p < 0.001), and increased the survival rate
(p = 0.03) with no postoperative adverse events. Yonemura
et al. [36] randomized 139 patients into 3 arms: surgery
alone, surgery with HIPEC and intraperitoneal chemother-
apy without hyperthermia. The 5-year survival rate was
61% in the HIPEC group as opposed to 43% and 42% in
the other two groups. In 2001 Kim and Bae [37] published
the results of a controlled study on 103 patients presenting
with a gastric carcinoma with invasion of the serosa,
who underwent surgical resection alone or associated
with HIPEC. The 5-year survival rate was significantly
higher in the experimental group when stage IV patients
were excluded (p = 0.0379). The most common types of
recurrence were locoregional in the HIPEC group and
peritoneal in the control group. Yan et al. [38] published a
meta-analysis which also demonstrated that using HIPEC
as an adjuvant treatment significantly improved the
survival rates of patients with stomach cancer (HR = 0.60;
CI 95% = 0.43 to 0.83; p = 0.002). This meta-analysis
suggested that intraperitoneal chemotherapy delivered
intraoperatively with hyperthermia was a more effectiveapproach than the delayed regimen. More recently, another
meta-analysis also showed the potential benefit of using
HIPEC for patients with an advanced gastric cancer in
an adjuvant setting [39]. The benefit of using HIPEC as
an adjuvant treatment for advanced gastric cancer has
been reported in several randomized studies and a meta-
analysis [38]. However these studies included patients
who were almost exclusively of Asian origin. It has
been formally demonstrated that Asian and Caucasian
gastric cancers differ in terms of epidemiology, diagnosis,
treatment and prognosis. On the subject of lymph node
dissection for example, several randomized studies in Asia
and Japan have validated D2 dissection. In Europe, two
randomized studies were carried out to assess the benefit
of D2 dissection and the conclusions of these studies differ
from the Asian studies [8,40].
Given that curative treatment failure in Western coun-
tries is mainly due to peritoneal recurrence and that a
meta-analysis composed almost entirely of Asian studies
suggests the benefit of HIPEC as an adjuvant treatment, a




GASTRICHIP is a prospective, open, randomized multi-
center phase III clinical study aimed to evaluate the effects
of HIPEC with oxaliplatin on patients with gastric cancer
involving the serosa and/or lymph node involvement and/
or with positive cytology at peritoneal washing, treated by
D1-D2 curative gastrectomy (Figure 1 – Flow chart study).
Patients will be randomly assigned in a 1:1 ratio to: Arm
A: curative gastrectomy with D1-D2 lymph node dis-
section +HIPEC with oxaliplatin versus Arm B: curative
gastrectomy with D1-D2 lymph node dissection without
HIPEC.
Measures of outcomes and assessments
Primary outcome
Overall survival will be measured from the date of sur-
gery to the date of death or to the end of follow-up
(5 years).
Secondary outcomes
Efficacy (3-year and 5-year recurrence-free survivals) and
localization of recurrence, morbidity, and quality of life.
Main inclusion criteria
Patients 18 < age ≤ 75 years old with Karnofsky index ≥
70% with histologically evidenced resectable T3 or T4
gastric adenocarcinoma for which a curative gastrectomy is
scheduled, with invasion into the serosa and/or lymph node
metastasis (determined from data obtained by endoscopic
ultrasound and chest, abdomen and pelvis Computed
Figure 1 GASTRICHIP study flow-chart.
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(sampled during the preoperative laparoscopy) and/or
perforated gastric adenocarcinoma and/or Siewert III
adenocarcinoma of the cardia for which a gastrectomy
by exclusive abdominal laparotomy is scheduled [41].
Exclusion criteria
The following criteria will exclude patients: prior malig-
nant tumors with detectable signs of recurrence, gastric
stump adenocarcinoma, presence of comorbidities, notably
serious chronic diseases or organ failure, pregnancy or
breastfeeding, contraindication to any drug contained
in the chemotherapy regimen, life threatening toxicity
before surgery, distant metastases (liver, lung. ovaries,
etc.), tumoral infiltration of the head or body of the
pancreas, patients presenting an adenocarcinoma of the
cardia Siewert I or II, existence of any macroscopic
peritoneal implants, patients with clinically significant
ascites (> 500 cc) even if cytology is negative for cancer
cells, in the absence of other non-malignant causes of
ascites.
Randomization
At the time of gastrectomy, if the patient has given in-
formed, written consent and meets inclusion criteria, he
will be peroperatively randomized, using an interactive
Web response system. Randomization will be balanced
and stratified by investigating center; because of thecenter’s influence in the most studies that evaluated
HIPEC, and by the presence or absence of signet ring
cells, based on the findings of the preoperative biopsies
because of the recent demonstration of its particular
prognosis and its relative chemoresistance.
Treatments
Perioperative treatment
All validated perioperative treatments of gastric cancer
will be authorized. For patients receiving neoadjuvant
chemotherapy, surgery will be scheduled 2 to 4 weeks
after the last course of systemic chemotherapy.
The pre- and the post-surgery chemotherapy regimen
administrated to a patient must be the same except in
case of toxicity, or progression.
Pre-therapeutic work-up
Patients eligible for the study will be seen in clinics
following the explorative laparoscopy to check the inclu-
sion and exclusion criteria. The patient will be required
to give written informed consent to participate to this
clinical study before any non routine screening tests
or evaluations are conducted. Patients eligible for the
study will be seen in clinics following the explorative
laparoscopy to check the inclusion and exclusion criteria.
The following assessments should be performed: Per-
formance Status, upper intestinal endoscopy, endoscopic
ultrasound, Thoraco-Abdomino-Pelvic CT scan, PET Scan
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CA72.4 (optional); hemoglobin, leukocytes, neutrophils,
platelets, glycemia, AST, ALT, LDH, total bilirubin, alkalin
phosphatase, serum albumin, total protein, plasmatic
APTT, PT and INR; creatinine clearance and serum
creatinine. Staging videolaparoscopy of the abdominal
cavity and peritoneal cytology testing will be carried out
following the same procedure as during gastrectomy.
Patients with macroscopic peritoneal carcinomatosis not
visible during the preoperative morphological examina-
tions will be excluded from the study.
Preoperative work-up
Patients should be re-evaluated within 21 days before
surgical procedure. The following assessments should
be performed: Performance Status, Thoraco-Abdomino-
Pelvic CT scan, PET Scan (optional), laboratory exams:
serum CEA, CA19.9 and CA72.4 (optional); hemoglobin,
leukocytes, neutrophils, platelets, glycemia, AST, ALT,
LDH, total bilirubin, alkalin phosphatase, serum albumin,
total protein, plasmatic APTT, PT and INR; creatinine
clearance and serum creatinine, quality of life assessment
(QLQ-C30 and QLQ-STO 22).
Patients with evidence of metastatic disease will be
excluded from study.
Surgical technique
At the opening of the abdomen, surgical exploration
will be performed in order to compare data collected at
preoperative videolaparoscopy with current operative
findings including the effects coming from preoperative
chemotherapy, namely the downstaging as far as T par-
ameter is concerned, presence of serosal involvement
and its extent, the absence of distant metastases and
the feasibility of a D1-D2 resection with curative intent.
Peritoneal washing will then be performed: the abdomen
will be irrigated with 200 ml of 0.9% NaCl solution (normal
saline), left in the peritoneal cavity for 2 minutes and then
all fluid will be aspirated from the four abdominopelvic
quadrants [Left Upper Quadrant (LUQ) - Right Upper
Quadrant (RUQ) - Left Lower Quadrant (LLQ) - Right
Lower Quadrant (RLQ)]. All the collected fluid will be sent
to the corresponding lab, where specimens for regular
cytological analysis, cell blocks and immunohistochemistry
(ancillary cytological study) will be sent to the Centre de
Biologie et de Pathologie Est – Hospices Civils de Lyon.
All the patients will undergo a D1-D2 gastrectomy,
carried out according to Japanese guidelines and to
the European recommendations for the preservation
of spleen and pancreas [42]: lymphadenectomy will
consist of removal of nodal groups 2 to 9 as specified by
the JGCRS; group 1 will be added when total gastrectomy
is performed and group 12 in distal cancers. Ex vivo
separation of lymph node groups in individual containersbefore the surgical specimen is submitted to the path-
ologist is recommended. At the end of the gastrectomy
procedure the peritoneal washing will be repeated with
the same procedure.
Following randomization, the patients treated into the
experimental Arm receive intravenous 5-FU 400 mg/m2 +
calcium levofolinate 10 mg/m2) as systemic chemotherapy
induction for HIPEC 15 min before HIPEC started. At the
end of the procedure the patients in the experimental
Arm will undergo HIPEC.
HIPEC techniques
The HIPEC can be carried out by open or closed abdomen
technique. With the Open abdomen technique, after the
D2 resection is complete, the inflow catheter is positioned
in the gastric resection bed. Drains are placed through
separate stab wounds in the abdominal flanks and posi-
tioned between the liver and undersurface of the right
hemidiaphragm behind the spleen and in the pelvis.
Number of drains used is left to the surgeon’s discretion
and according to the specifications of the HIPEC circuit
used. One of the two temperature probes will be secured
near the tip of the inflow catheter and the other in the
pelvis. Using a monofilament running suture, the skin
edges are secured to the Thompson self retaining retractor,
and a plastic sheath is incorporated into these sutures to
create an open space beneath. A slit in the plastic cover is
made to allow the surgeon hand access to abdomen and
pelvis. During the perfusion all the anatomic structures
within the abdominal cavity are uniformly exposed to
heat and to chemotherapy. A roller pump forces the
chemotherapy solution (oxaliplatin 250 mg/m2 with 2
Liters of G5%/m2) into the abdomen through the inflow
catheter and pulls it out through the drains. A heat
exchanger keeps the intraperitoneal fluid at 42°-43°C.
After the intraoperative perfusion is complete (30 minutes),
the abdomen is closed and the drains are left in place
in the postoperative period until the discharge from the
peritoneal cavity subsides. With the Closed abdomen
technique, surgery is completed with anastomosis and
drains positioning as in the Open technique, the abdominal
wall sutured. External manual shaking of the abdomen
will be carried out for optimization of chemotherapy
distribution. The anastomoses will be constructed either
before or after HIPEC administration.
Follow-up
After HIPEC, patients will remain in the Intensive Care
Unit as long as required (it will be remained at the peri-
operative team’s discretion, depending on patient’s needs
and postoperative clinical progress). They will be evaluated
with clinical examination daily. Each day for the first week
and each third day thereafter, laboratory exams will be
performed in order to assess haematological, renal and
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will be evaluated according to the Common Terminology
Criteria for Adverse Events (CTC-AE V4.0) from the
National Cancer Institute.
Once an early postoperative follow-up four weeks after
gastrectomy, the visits of follow-up are based on the
date of the surgery every 3 months for the first 2 years
following surgical procedure and twice a year for the last
3 years. For all patients clinical follow-up with all events
and endpoints will be collected and analyzed during
5 years from their inclusion (except for patients died,
lost of follow-up or expressed their refusal).Criteria for premature discontinuation of the patient’s
study participation
Patients can be withdrawn from the study under the fol-
lowing circumstances: death, disease progression, initiation
of alternate anti-neoplastic therapy, toxicity, intercurrent
illness, non compliance (including loss of patient to follow-
up), voluntary withdrawal, failure to meet the eligibility
criteria.Premature closure of the study
Study participation by individual sites or the entire study
may be prematurely terminated, if in the opinion of the
sponsor, there is sufficient reasonable cause. Any investi-
gator who wants to discontinue his/her participation to
the study must immediately inform the sponsor in writing
of this decision. Written notification documenting the
reason for study termination will be provided to the
investigator by the terminating party.
Examples of circumstances that may warrant termin-
ation include: failure to enter patients at an acceptable
rate, insufficient adherence to protocol requirements,
insufficient complete and/or evaluable data, frequency
and/or unexpected severity of the toxicity, unacceptable
toxicity. Each fatal event occurring within the 60th post-
operative days will be immediately reported to the spon-
sor and to Data and Safety Monitoring Board (DSMB)
members. The DSMB will be provided with the descrip-
tion of the fatal events to determine if the death has to
be considered as a toxic one.
The statistical stopping rules are the following: for each
toxic fatal event in the HIPEC arm, an analysis comparing
the total number of patients included to the number of
patients satisfying maximum toxic fatal event criteria
will be performed to determine if the study should be
stopped. This analysis will be realized with the Kramar
sequential method [43] as implemented in the R-package
[44]. This analysis will be performed using the following
parameters: the maximum acceptable percentage of toxic
deaths is fixed at 10% [the global alpha at 10%, and gamma
at 4 (i.e., high alpha level at the beginning of the trial)],considering that the first toxic fatal event will not be taken
into account.
Sample size calculation and statistical considerations
This study is designed as a randomized phase III in order
to compare the 5-year overall survival in patients with
advanced gastric carcinoma randomized to hyperthermic
intraperitoneal chemotherapy administration versus that
of patients randomized to control arm.
The hypotheses are the following: 5-year overall survival
in the control group of about 30% [9,10]; 5-year overall
survival in the intervention group of about 45% (i.e. an HR
of 0.67) [45]; a maximum follow-up time of 5 years; an
alpha of 5%, two-sided. With this hypothesis and to have a
80% power, a total of 306 patients will have to be random-
ized. Since 5% of patients are expected to excluded during
surgery (peritoneal carcinomatosis), a total of 322 patients
will be included.
The effectiveness analysis will be carried out on the
intention-to-treat population, defined as all patients
included. A second analysis will be conducted on the
“treated” population, determined according to the
treatment actually administered (per protocol analysis).
Overall survival will be measured from the date of surgery
up to the date of death, regardless of the cause, or to the
end of follow-up (5 years). The Kaplan-Meier method will
be used to estimate the survival curves. Median survival
will also be given and differences between the two groups
assessed using a logrank test. This analysis will then be
confirmed using a Cox regression analysis taking into
account the center effect (frailty Cox model). The condi-
tions for using the Cox regression analysis will be checked.
An intermediate analysis of toxicity will be realized at
least every six months or every 50 patients randomized
from the start of patients’ recruitment. The number of
SAEs and AEs of severe (grade III-IV) with their ac-
countability will be described.
Ancillary study
A cytological ancillary study will be performed. The aim
of this exploratory study is to compare the incidence of
positive peritoneal cytology pre- and post-gastrectomy
in the two arms of the study (Am A and Arm B), and
to assess its impact on 5-year survival. A standardized
procedure for peroperative peritoneal cytological sam-
pling was previously approved under a large, French,
multi-center prospective study (EVOCAPE 2, PHRC
2001 Funding) and will be followed for the pre- and
post-gastrectomy sampling [46]. Samples will be separated
into 2 aliquots. After sedimentation overnight at room
temperature, the material will be centrifuged at 1500 RPM
for 5–10 minutes. The cell pellet will be aspirated,
smeared on Superfrost PLUS glass slide and dessicated
(2 slides) or fixed with methanol (one additional). Smears
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automaton, and with Papanicolaou. For every case, the
remaining cell pellet will be submitted to the cell block
technique (Shandon Cytoblock Kit®) for Haematoxylin and
eosin control and immunohistochemistry. Immunohisto-
chemistry performed on cell blocks using at least CEA
(monoclonal and polyclonal) and cytokeratin 20, the
Cytokine-like High Mobility Group Box 1 (HMGB1) [47]
will also be considered. Positive samples will be defined by
the presence of either tridimensional clusters of malignant
cells, or by the presence of unequivocal isolated malignant
cells. The presence of cell and nuclear atypias (cell balls
not mesothelial in origin, epithelial cells with increased
N/C ratio, enlarged nuclei, irregular nuclear borders,
and prominent nucleoli) will be considered necessary for
the positive morphological diagnosis, as previously reported
[46]. Additionally, cases with CEA- and/or CK20-reactive
epithelial cells will be considered positive, whatever their
morphological aspect. Negative samples will be defined by
the absence of malignant cells after conventional stains and
immunohistochemistry (no CEA and/or CK20 immunore-
activity). Peritoneal samples taken before and after surgery
will be fixed with 1/3 carbowax (20% polyethylene-glycol
1500 in 50% ethanol) and sent as rapidly as possible to
the laboratory in 100 to 500 mL vials, according to the
amount of fluid. Cells will be allowed to sediment over-
night at room temperature. The lower part of the fluid
will then be aspirated and treated as previously described
(see the lab. technique) for smearing, cell blocks and
immunohistochemistry.
The number of pre- and post-gastrectomy positive
cytologies will be calculated. The percentage of pre- and
post-gastrectomy positive cytologies will be compared
using Mcnemar’s test. A Cox regression model will be
used to assess the impact of peritoneal cytology on 5-year
overall survival. The conditions for using Mcnemar’s test
and the Cox regression analysis will be checked.
Ethical considerations, information giving and written
informed consent
The study protocol was approved by the Institutional
Review Board, the Sud Est IV ethics committee on the
12 of February 2013 and the French National Agency for
Medicines and Health (ANSM) on the 26 of April 2013
under the number 2012-005748-12. The study has been
registered on the ClinicalTrial.gov website under the
identification number NCT01882933. The GASTRICHIP
study complies with the Declaration of Helsinki rules, the
principles of Good Clincal Pratice guidelines and the Data
Protection Act. The trial will also be carried out in keeping
with local legal and regulatory requirements.
For each patient recruited into the study, written in-
formed consent is essential prior to inclusion into the
study after extensive information about the intent of thestudy, the study regimen, potential associated risks and
side effects as well as potential alternative therapies.
The investigator will not undertake any diagnostic mea-
sures specifically required for the clinical trial until valid
consent has been obtained.
Discussion
The benefit of using HIPEC as an adjuvant treatment for
advanced gastric cancer has been reported in several
randomized studies and two meta-analyses [38,39]. How-
ever these studies included patients who were almost
exclusively of Asian origin. It has been formally demon-
strated that Asian and Caucasian gastric cancers differ
in terms of epidemiology, diagnosis, treatment and
prognosis. On the subject of lymph node dissection for
example, several randomized studies in Asia and Japan
have validated D2 dissection. In Europe, two random-
ized studies were carried out to assess the benefit of D2
dissection and the conclusions of these studies differ
from the Asian studies [8,40]. This is the reason why
the benefit of adjuvant HIPEC should be evaluated on
Caucasian gastric cancers.
The chemotherapeutic agents to be used for HIPEC
are selected on the basis of their ability to rapidly pro-
duce a direct cytotoxic effect (their action should not be
dependent on the cell cycle). The concomitant administra-
tion of heat increases the cytotoxic effect. The duration
of exposure is related to the effectiveness of the intra-
peritoneal chemotherapy and studies investigating the
pharmacokinetics of HIPEC have shown that most of the
medication is absorbed during the first hour of perfusion.
Furthermore, it has been shown that the rate of postop-
erative complication is directly linked to the duration
of surgical procedures: HIPEC should therefore be admin-
istered over the shortest possible period of time in which
it is able to produce its cytotoxic effect.
Mitomycin C and cisplatin are the two antimitotic agents
most commonly used for HIPEC and have therefore been
studied the most and shown to meet requirements for this
treatment. They have been used in combination by several
authors [36,48-50] for the integrated treatment of periton-
eal carcinomatosis. The reinforcement of their cytotoxicity
through the concomitant administration of heat and their
synergistic action have both been demonstrated. Further-
more, they only generate minimal chemical peritonitis.
Good results for the treatment of gastric cancer in terms
of both response and tolerance have been obtained using
oxaliplatin in systemic perioperative chemotherapy proto-
cols [51]. Recently, excellent results in treating colorectal
peritoneal carcinomatosis have been reported for the
use of HIPEC with oxaliplatin, with an exposure time of
just 30 minutes. Furthermore, a French randomized, phase
III study is currently assessing the use of HIPEC with
oxaliplatin associated with complete cytoreductive surgery
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three studies used a dose of 460 mg/m2 of oxaliplatin for
the open-abdomen technique and 350 mg/m2 for the
closed-abdomen technique, administered in 2 liters/m2 of
5% glucose with the systemic administration of induction
chemotherapy using FU/Leucovorin (400 mg/m2 5-FU
and 20 mg/m2 of folic acid) to increase the cytotoxic effect
of the oxaliplatin. Glehen et al. recently published a report
on the French experience in the curative treatment of
gastric peritoneal carcinomatosis [30]. The mortality rate
was high, and reached 6%. This may be explained by the
fact that the gastrectomy-HIPEC association increases the
risk of severe postoperative complications. It would seem
preferable to arbitrarily reduce the dose of oxaliplatin
(250 mg/m2) in order to avoid an excessive rate of post-
operative complications resulting from the experimental
treatment.
The incidence of signet ring cell adenocarcinoma is
steadily increasing in Western countries [52,53]. Recent
data has suggested not only that is has a negative prog-
nostic value [22], but that it is also chemo-resistant
[54,55] which calls into question the use of systemic
neoadjuvant chemotherapy for this histologic type. Surgery
remains the undisputed lynchpin of the curative treatment
of gastric adenocarcinoma (subtotal or total gastrectomy
with D2 lymph node dissection without splenectomy and
pancreatectomy), but if systemic perioperative chemo-
therapy is to be recommended in Europe, the choice of
perioperative treatment should be discussed on a case-by-
case basis at Multi-Disciplinary Team meetings in order
to take into account the patient’s pre and post-surgery
general and nutritional state of health, the histology, and
the preoperative and pathologic staging. Free intraperi-
toneal cancer cells originating from the primary tumor
which invade the serosa prior to resection contribute to
the peritoneal recurrence of resectable stomach cancer.
Free cancer cells in the peritoneal cavity may also originate
from the blood or the lymph which transport tumor
cells to the surgical site. These cells may also originate
from lymph node metastatis. Indeed, the surgical trauma
resulting from the excision of the primary tumor provokes
the release of tumor emboli in the peritoneal cavity which
rapidly adhere the surface revealed by the removal of the
tumor. Immediately after the intervention the resection
site and traumatized peritoneal surfaces become covered
in a fibrinous exudate which entraps tumor cells and
protects them from the body’s defense mechanisms.
This whole process constitutes the theory of what Paul
Sugarbaker has called “tumor cell entrapment” [56]. This
is a key phenomenon which needs to be understood in
order to fully comprehend the pathogenesis of recurrence,
both at the site of resection and on the peritoneal surfaces,
and to assess the beneficial effects of adjuvant periopera-
tive intraperitoneal chemotherapy.The increased incidence of postoperative positive periton-
eal cytology has only been suggested in small Asian studies
[21,57]. Whilst the prognostic value of positive peritoneal
cytology prior to resection seems to be well established
[20,58], the same cannot be said for post-resection periton-
eal cytology whose prognostic value remains controversial
but which may represent a key prognostic factor for
peritoneal and locoregional recurrence.
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